Nanosonics Limited

Equities

NAN

AU000000NAN9

Advanced Medical Equipment & Technology

Delayed Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
2.76 ^AUD	-1.78%		-1.78%	-37.27%

Mar. 15	Nanosonics Chief Technology Officer to Retire	MT
Feb. 26	Nanosonics Shares Fall 8% as H1 FY24 Revenue Falls 2% to AU$79.6 Million; EPS Slips to AU$0.0202	MT

Nanosonics Limited Provides Revenue Guidance for the Fiscal Year 2022

July 24, 2022 at 06:44 pm EDT

Nanosonics Limited provided revenue guidance for the fiscal year 2022. The company expects to report revenue of $120.3 million for fiscal year 2022, representing a 17% increase compared with fiscal year 2021.

Latest news about Nanosonics Limited

Nanosonics Chief Technology Officer to Retire	Mar. 14	MT
Nanosonics Shares Fall 8% as H1 FY24 Revenue Falls 2% to AU$79.6 Million; EPS Slips to AU$0.0202	Feb. 25	MT
Transcript : Nanosonics Limited, H1 2024 Earnings Call, Feb 26, 2024	Feb. 25
Nanosonics Reports H1 FY24 Revenue Down 2% to AU$79.6 Million; EPS of AU$0.0202	Feb. 25	MT
Nanosonics Reports H1 FY24 Revenue Down 2% to AU$79.6 Million; Diluted EPS of AU$0.0202	Feb. 25	MT
Nanosonics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Nanosonics Limited Provides Earnings Guidance for the First Half, Second Half and Full Year of 2024	Jan. 23	CI
Transcript : Nanosonics Limited - Shareholder/Analyst Call	Nov. 02
Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023	23-09-06	CI
Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023	23-08-24	CI
Nanosonics Grows Fiscal 2023 Profit, Revenue; Shares Down 3%	23-08-22	MT
Nanosonics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-21	CI
Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023	23-07-18	CI
Nanosonics CFO Resigns	23-05-12	MT
Nanosonics Announces Company Secretary Changes	23-05-11	CI
Nanosonics Announces the Resignation of McGregor Grant as Chief Financial Officer	23-05-11	CI
Nanosonics Fiscal H1 Profit, Revenue Rise	23-02-23	MT
Nanosonics to Seek M&A	23-02-22	CI
Transcript : Nanosonics Limited, H1 2023 Earnings Call, Feb 23, 2023	23-02-22
Nanosonics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Heramed Appoints President for North American Unit	23-01-23	MT
Energy stocks push Australian shares lower; BHP Group rises	23-01-18	RE
Transcript : Nanosonics Limited - Shareholder/Analyst Call	22-11-17
Transcript : Nanosonics Limited, 2022 Earnings Call, Aug 23, 2022	22-08-22
Nanosonics Limited Provides Revenue Guidance for the Fiscal Year 2022	22-07-24	CI

Chart Nanosonics Limited

Duration

Period

More charts

Company Profile

Nanosonics Limited is an Australia-based infection prevention company. The Company's principal activities include the manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. It is focused on the research, development, and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generate a sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. Its products include trophon2, Nanosonics Auditpro, and trophon electron paramagnetic resonance (EPR). The Companyâs trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics Auditpro provides real-time intelligence on ultrasound probes, operators, and infection control events to manage infection prevention practices across organizations.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-18 - Q4 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Nanosonics Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.76 AUD

Average target price

3.204 AUD

Spread / Average Target

+16.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NANOSONICS LIMITED	-37.27%	552M
THERMO FISHER SCIENTIFIC	+8.78%	219B
DANAHER CORPORATION	+8.24%	187B
INTUITIVE SURGICAL, INC.	+11.16%	134B
BOSTON SCIENTIFIC CORPORATION	+26.12%	101B
SIEMENS HEALTHINEERS AG	+0.30%	62.27B
EDWARDS LIFESCIENCES CORPORATION	+16.21%	52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.49B
AGILENT TECHNOLOGIES, INC.	-1.11%	40.79B
GE HEALTHCARE TECHNOLOGIES INC.	+12.16%	39.35B

Other Advanced Medical Equipment & Technology